Commentary
This article discusses the unprecedented toll of COVID-19 and how it jumpstarted the race towards potential COVID-19 vaccinations, which have been developed in less than a year. It discusses how this feat was accomplished, and how clinical development, manufacturing scale-up and distribution are occurring in parallel for the four COVID-19 vaccine front-runners. It also discusses the many challenges that still lie ahead.
Review
This review aims to assess the efficacy and safety of available therapies for COVID-19 in light of current evidence. These treatment options are compared based on their impact on symptom management, inpatient length of stay, and overall morbidity and mortality.
Editorial
The Senior Editors of Drugs in Context provide us with their expert opinion on the events of 2020 and what lies ahead in 2021.
Corrigendum
The authors wish to make the following corrections to their article: Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. Drugs in Context 2020; 9: 2020-9-4. DOI: 10.7573/dic.2020-9-4
Review
This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.
